Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis

Histopathology

Volumn 61, Issue 1, 2012, Pages 98-106

  Cha, Seung Ick ^a,b   Chang, Christine S ^a   Kim, Eun Kyung ^a,c   Lee, Jae W ^a   Matthay, Michael A ^a   Golden, Jeffrey A ^a   Elicker, Brett M ^a   Jones, Kirk ^d   Collard, Harold R ^a   Wolters, Paul J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kyungpook National University School of Medicine   (South Korea)

^c CHA University   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chloroacetate esterase; Eosinophil; Hypersensitivity pneumonitis; Idiopathic interstitial pneumonia; Systemic sclerosis

Indexed keywords

CHYMASE; EOSINOPHIL PEROXIDASE;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; CELL DENSITY; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; EOSINOPHIL; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MAST CELL; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ALVEOLITIS, EXTRINSIC ALLERGIC; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CELL COUNT; CHRONIC DISEASE; CHYMASES; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOENZYME TECHNIQUES; LUNG; MALE; MAST CELLS; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 84862892172     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04197.x     Document Type: Article

References (45)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161; 646-664.
2. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002; 165; 277-304.
3. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 2010; 35; 496-504.
4. Mekori YA. The mastocyte: the 'other' inflammatory cell in immunopathogenesis. J. Allergy Clin. Immunol. 2004; 114; 52-57.
5. Liu J, Divoux A, Sun J et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med. 2009; 15; 940-945.
6. Conti P, Castellani ML, Kempuraj D et al. Role of mast cells in tumor growth. Ann. Clin. Lab. Sci. 2007; 37; 315-322.
7. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis * Annu. Rev. Immunol. 2009; 27; 165-197.
8. Sun J, Sukhova GK, Wolters PJ et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat. Med. 2007; 13; 719-724.
9. Miyazawa S, Hotta O, Doi N, Natori Y, Nishikawa K. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int. 2004; 65; 2228-2237.
10. Jin D, Takai S, Shiota N, Miyazaki M. Roles of vascular angiotensin converting enzyme and chymase in two-kidney, one clip hypertensive hamsters. J. Hypertens. 1998; 16; 657-664.
11. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003; 107; 2555-2558.
12. Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha. J. Immunol. 2001; 167; 4008-4016.
13. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J. Am. Soc. Nephrol. 2008; 19; 2254-2261.
14. Inoue Y, King TE Jr, Tinkle SS, Dockstader K, Newman LS. Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am. J. Pathol. 1996; 149; 2037-2054.
15. Hunt LW, Colby TV, Weiler DA, Sur S, Butterfield JH. Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo Clin. Proc. 1992; 67; 941-948.
16. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. Am. J. Respir. Crit. Care Med. 1995; 152; 2163-2169.
17. Edwards ST, Cruz AC, Donnelly S et al. c-Kit immunophenotyping and metalloproteinase expression profiles of mast cells in interstitial lung diseases. J. Pathol. 2005; 206; 279-290.
18. Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS. Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181; 206-217.
19. Inoue Y, King TE Jr, Barker E, Daniloff E, Newman LS. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 2002; 166; 765-773.
20. Ruoss SJ, Hartmann T, Caughey GH. Mast cell tryptase is a mitogen for cultured fibroblasts. J. Clin. Invest. 1991; 88; 493-499.
21. Okazaki T, Hirota S, Xu ZD et al. Increase of mast cells in the liver and lung may be associated with but not a cause of fibrosis: demonstration using mast cell-deficient Ws/Ws rats. Lab. Invest. 1998; 78; 1431-1438.
22. Mori H, Kawada K, Zhang P, Uesugi Y, Sakamoto O, Koda A. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int. Arch. Allergy Appl. Immunol. 1991; 95; 195-201.
23. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23; 581-590.
24. Hanak V, Golbin JM, Hartman TE, Ryu JH. High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 2008; 134; 133-138.
25. Miller MR, Hankinson J, Brusasco V et al. Standardisation of spirometry. Eur. Respir. J. 2005; 26; 319-338.
26. Macintyre N, Crapo RO, Viegi G et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 2005; 26; 720-735.
27. Gonzalez-Arevalo A, Gomez-Arnau JI, delaCruz J, Lacoma F, Galdos P, Garcia-del-Valle S. Oxygen consumption measurement: agreement between the closed-circuit PhysioFlex anesthesia machine and the Deltatrac II indirect calorimeter. Anesth. Analg. 2003; 97; 1680-1685.
28. Hanak V, Ryu JH, de Carvalho E et al. Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir. Med. 2008; 102; 852-856.
29. Enomoto N, Suda T, Kato M et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest 2006; 130; 22-29.
30. Flaherty KR, Colby TV, Travis WD et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am. J. Respir. Crit. Care Med. 2003; 167; 1410-1415.
31. King TE Jr, Schwarz MI, Brown K et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med. 2001; 164; 1025-1032.
32. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166; 173-177.
33. Tiitto L, Bloigu R, Heiskanen U, Paakko P, Kinnula VL, Kaarteenaho-Wiik R. Relationship between histopathological features and the course of idiopathic pulmonary fibrosis/usual interstitial pneumonia. Thorax 2006; 61; 1091-1095.
34. Collard HR, Cool CD, Leslie KO, Curran-Everett D, Groshong S, Brown KK. Organizing pneumonia and lymphoplasmacytic inflammation predict treatment response in idiopathic pulmonary fibrosis. Histopathology 2007; 50; 258-265.
35. Boomars KA, Wagenaar SS, Mulder PG, van Velzen-Blad H, van den Bosch JM. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 1995; 50; 1087-1092.
36. Fujimoto K, Kubo K, Yamaguchi S, Honda T, Matsuzawa Y. Eosinophil activation in patients with pulmonary fibrosis. Chest 1995; 108; 48-54.
37. Jegal Y, Kim DS, Shim TS et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171; 639-644.
38. Flaherty KR, Mumford JA, Murray S et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168; 543-548.
39. Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168; 538-542.
40. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009; 31; 425-437.
41. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur. Respir. J. 1998; 11; 1218-1221.
42. Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2008; 10; 287-301.
43. Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clin. Chest Med. 2004; 25; 749-758.
44. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc. 2006; 3; 364-372.
45. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006; 3; 350-356.